In a historic moment for the healthcare industry, Eli Lilly has become the first health company in the world to hit a $1 trillion market value. This major milestone places the Indianapolis-based drugmaker in a rare league of global giants, highlighting the growing influence of pharmaceutical innovation on the stock market and the future of medicine.
A Record-Breaking Day for Eli Lilly
On Friday, Eli Lilly’s stock briefly crossed the $1 trillion valuation mark during morning trading. Though the stock slightly pulled back later in the day, shares remained strong, trading at around $1,048 each.
With this, Eli Lilly has joined a small list of U.S. companies to achieve this valuation — and is now only the second non-tech company, after Warren Buffett’s Berkshire Hathaway, to hit the $1 trillion milestone.
What’s Driving Eli Lilly’s Massive Growth?
The company’s success has been powered mainly by two blockbuster drugs:
- Mounjaro – a treatment for type 2 diabetes
- Zepbound – a weight loss drug approved for obesity
Both drugs are based on tirzepatide, a groundbreaking molecule that has become one of the most in-demand treatments worldwide.
Key Sales Figures:
| Drug | Q3 2025 Revenue | Year-over-Year Growth |
|---|---|---|
| Mounjaro | $6.52 billion | +109% |
| Zepbound | $3.59 billion | +184% |
The company expects these numbers to continue rising as insurance coverage improves, more doctors prescribe these medications, and the global demand for weight loss treatments explodes.
What’s Next for Eli Lilly?
Eli Lilly has big plans ahead. It is set to launch an oral version of its weight loss drug in 2026 — a convenient alternative for patients who prefer not to take injections. This could open doors to millions more users, especially those hesitant to start injectable treatments.
According to industry experts, the global market for weight loss drugs could exceed $150 billion by the early 2030s. With a strong pipeline, Eli Lilly is well-positioned to dominate the space.
Rivals and Industry Competition
While Eli Lilly leads the pack for now, it’s not alone in this space. Other major players include:
- Novo Nordisk – maker of Ozempic and Wegovy, two hugely popular GLP-1 drugs.
- Pfizer – recently acquired Metsera, an obesity drug startup, for $10 billion, signalling its serious entry into the market.
The rising competition could reshape the pharmaceutical landscape, but for now, Eli Lilly holds the crown.
Eli Lilly’s Legacy of Medical Innovation
Founded in 1876, Eli Lilly has a long history of bringing revolutionary treatments to the world. Some of its major achievements include:
- 1923: Introduced the world’s first commercial insulin
- 1952: Went public on the U.S. stock exchange
- 1980s: Released Prozac, a widely-used antidepressant
- Polio vaccine: Played a key role in early vaccine development
Its recent turnaround began in May 2022, when tirzepatide (Mounjaro) was approved for diabetes. By late 2023, it received approval as Zepbound for obesity, marking the beginning of the company’s newest and most lucrative chapter.
Total 2024 Sales:
| Drug | 2024 Sales Revenue |
|---|---|
| Mounjaro | $11.54 billion |
| Zepbound | $4.93 billion |
